Provectus Biopharmaceuticals, Inc. (PVCT)
OTCMKTS · Delayed Price · Currency is USD
0.0598
-0.0002 (-0.39%)
At close: Dec 26, 2025
PVCT Revenue
Provectus Biopharmaceuticals had revenue of $350.44K in the twelve months ending September 30, 2025, down -51.59% year-over-year. In the year 2024, Provectus Biopharmaceuticals had annual revenue of $617.14K with 10.66% growth.
Revenue (ttm)
350.44K
Revenue Growth
-51.59%
P/S Ratio
71.68
Revenue / Employee
58.41K
Employees
6
Market Cap
25.12M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 617.14K | 59.43K | 10.66% |
| Dec 31, 2023 | 557.71K | -431.33K | -43.61% |
| Dec 31, 2022 | 989.04K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Northwest Biotherapeutics | 937.00K |
Provectus Biopharmaceuticals News
- 2 months ago - Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway Activation for Improving Hepatitis B Vaccine Efficacy - GlobeNewsWire
- 3 months ago - Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer - GlobeNewsWire
- 6 months ago - Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer - GlobeNewsWire
- 7 months ago - Provectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of Stockholders - GlobeNewsWire
- 1 year ago - Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus's Spinoff Company for Rose Bengal-Based Eye Drugs - GlobeNewsWire
- 1 year ago - Provectus Biopharmaceuticals, Inc. (PVCT) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 1 year ago - Provectus Biopharmaceuticals GAAP EPS of $0.00, revenue of $0.11M - Seeking Alpha
- 1 year ago - Provectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference Call - GlobeNewsWire